Effect of Bisoprolol, a .BETA.1-Selective .BETA.-Blocker, on Lipid and Glucose Metabolism and Quality of Life in Elderly Patients with Essential Hypertension.

Haneda, Takashi; Ido, Akira; Fujikane, Toshiaki; Tanaka, Hideichi; Tanazawa, Satoshi; Morimoto, Hideo; Kato, Jun; Kanaya, Kenichi; Honda, Hiroki; Sakai, Hirotsuka; Akita, Nobuyuki; Hirayama, Tomoya; Onodera, Sokichi; Kikuchi, Kenjiro

doi:10.3143/geriatrics.35.33

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beta-blockers were found to be effective in increasing quality of life in case of heart failure as well as hypertension ( Fowler 1998 ; Haneda et al 1998 ; Reddy and Dunn 2000 ). Due to their antianginal effect, they also enhance quality of life in case of ischemic heart disease.…”

Section: Discussionmentioning

confidence: 99%

Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial

Kardas¹

2007

Vascular Health and Risk Management

View full text Add to dashboard Cite

Background: A randomized, controlled trial was conducted in an outpatient setting to examine the effect of beta-blocker dosing frequency on patient compliance, clinical outcome, and health-related quality of life in patients with stable angina pectoris. Methods: One hundred and twelve beta-blockers-naive outpatients with stable angina pectoris were randomized to receive betaxolol, 20 mg once daily or metoprolol tartrate, 50 mg twice daily for 8 weeks. The principal outcome measure was overall compliance measured electronically, whereas secondary outcome measures were drug effectiveness and health-related quality of life. Results: The overall compliance was 86.5 ± 21.3% in the betaxolol group versus 76.1 ± 26.3% in the metoprolol group (p < 0.01), and the correct number of doses was taken on 84.4 ± 21.6% and 64.0 ± 31.7% of treatment days, respectively (p < 0.0001). The percentage of missed doses was 14.5 ± 21.5% in the once-daily group and 24.8 ± 26.4% in the twice-daily group (p < 0.01). The percentage of doses taken in the correct time window (58.6% vs 42.0%, p = 0.01), correct interdose intervals (77.4% v 53.1%, p < 0.0001), and therapeutic coverage (85.6% vs 73.7%, p < 0.001) were signifi cantly higher in the once-daily group. Both studied drugs had similar antianginal effectiveness. Health-related quality of life improved in both groups, but this increase was more pronounced in the betaxolol arm in some dimensions. Conclusions:The study demonstrates that patient compliance with once-daily betaxolol is signifi cantly better than with twice daily metoprolol. Similarly, this treatment provides better quality of life. These results demonstrate possible therapeutic advantages of once-daily over twice-daily beta-blockers in the treatment of stable angina pectoris.

show abstract

Section: Discussionmentioning

confidence: 99%

Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial

Kardas¹

2007

Vascular Health and Risk Management

View full text Add to dashboard Cite

show abstract

“…When using beta‐blockers in these subgroups, highly beta‐1 selective agents without intrinsic sympathomimetic activity, e.g. atenolol, metoprolol, bisoprolol, or nebivolol should be chosen (69). Vascular remodelling is hardly affected by diuretics and beta‐blockers.…”

Section: Side‐effects Of Antihypertensive Agentsmentioning

confidence: 99%

Arterial hypertension and ischaemic stroke

Droste

Ritter

Dittrich

et al. 2003

Acta Neurologica Scandinavica

View full text Add to dashboard Cite

show abstract

“…Bisoprolol istotnie poprawiał jakość życia w obu grupach. Bradykardię odnotowano tylko u jednego pacjenta w grupie osób w podeszłym wieku [46]. Wyniki tych badań sugerują, że bisoprolol jest bezpiecznym i użytecznym lekiem, w dawce skutecznej terapeutycznie nie ma wpływu na gospodarkę węglowodanową i lipidową.…”

Section: Bisoprololunclassified

Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review

FULARSKA

OLESZKO

WĄSIEWICZ

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Blood sugar level impairment, especially diabetes mellitus (DM) is a significant problem. DM leads to many serious complications. Patients suffering from cardiac failure (HF) and diabetes have a risk of hospitalization increased 1.5 times compared to the control group without DM. That is why it is very important to keep appropriate glycemic control. β-blockers, are considered to cause a blood glucose level impairment. The relationship between the use of β-blockers and the development of DM is one of the most interesting and controversial issues in diabetology. Despite many benefits, some doctors are reluctant to prescribe β-blockers because of perceived negative metabolic effects.Aim of study: The purpose of the study was to review the literature describing oral β-blockers, used in HF, influence on glucose metabolism and to discover the best β-blocker treatment for cardiac failured diabetics and prediabetics. Methods: A systemic review was conducted using PubMed, ScienceDirect, Google Scholar databases. The search strategy was based on the following terms: beta-blocker, blood glucose level, metoprolol, nebivolol, carvedilol, bisoprolol. Results: β-blockers differ in terms of their mechanism of action and their effects on glucose metabolism. Metoprolol is associated with a worsening of glucose and lipid control. Bisoprolol have a neutral impact on glucose metabolism. Vasodilating β-blockers may improve glycemic profile.Conclusions: All four β-blockers used in HF have similar blood pressure lowering effect but different metabolic effect. Metoprolol should not be used as a drug of choice in patients with impaired glucose metabolism. Bisoprolol, nebivolol or carvedilol may be recommended as a drug of choice in patients with cardiac failure and impaired carbohydrate metabolism. The choice between bisoprolol and vasodilating β-blockers in patients with glycemic disorders is still an unresolved issue.

show abstract

Effect of Bisoprolol, a .BETA.1-Selective .BETA.-Blocker, on Lipid and Glucose Metabolism and Quality of Life in Elderly Patients with Essential Hypertension.

Cited by 10 publications

References 0 publications

Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial

Compliance, clinical outcome, and quality of life of patients with stable angina pectoris receiving once-daily betaxolol versus twice daily metoprolol: a randomized controlled trial

Arterial hypertension and ischaemic stroke

Beta-blockers used in cardiac failure and blood glucose level impairment - a literature review

Contact Info

Product

Resources

About